RxDoctor Payments Data

Lindsey Mochel

Primary Care · Lakewood, CONPI 1245780949

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Novo Nordisk at 27.0% of the total. Reporting peaked in 2024 at $199 and has fallen 62.2% since, to $75 in 2025.

$534in general payments, 2019–2025

Across 30 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$144
  • Amgen$102
  • Lilly USA, LLC$95
  • Novartis$54
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$34
  • Medtronic$31
  • plus $73 from 4 others

What the payments were for

  • Food & beverage$534100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$534 in reported general payments places this provider in the 65th percentile of 112 primary care providers in Colorado.

See all primary care providers in Colorado

Medicare billing

Part B allowed, 2024
$2,173
Medicare patients
77
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$94,337
EliquisApixaban41$43,574
RybelsusSemaglutide27$34,875
MounjaroTirzepatide22$34,743
XareltoRivaroxaban15$21,138
SymbicortBudesonide/Formoterol Fumarate30$10,986
JardianceEmpagliflozin13$10,022
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$8,051
Breo ElliptaFluticasone/Vilanterol18$7,306
Spiriva HandihalerTiotropium Bromide12$6,540
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$3,858
Novolog FlexpenInsulin Aspart13$2,821
Albuterol Sulfate HfaAlbuterol Sulfate82$2,743
Atorvastatin Calcium313$2,216
Gabapentin140$1,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$144$129,212102 claims
PfizerEliquis$14$43,57441 claims
Lilly USA, LLCMounjaro$95$34,74322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 112 primary care providers in Colorado.

Other primary care in Lakewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →